iPierian

About iPierian

iPierian, Inc. operated as a biopharmaceutical company with a sharp focus on leveraging induced pluripotent stem cells (iPSCs) for therapeutic discovery, particularly in the neurodegenerative disease space. The company was formed in 2009 through a merger between Pierian, founded by scientists from the Harvard Stem Cell Institute, and iZumi Bio. This strategic combination brought together significant venture capital and expertise.

The company's core technology centered on using patient-derived iPSCs to create cellular models of diseases like Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis. This approach allowed researchers to study the earliest stages of neurodegeneration in human cells, a significant departure from relying on end-stage autopsy tissues. By creating cortical neurons, motor neurons, and other brain cells from these stem cells, iPierian aimed to discover and validate novel drug targets. The primary business model was to develop a proprietary pipeline of drug candidates, specifically monoclonal antibodies, and to form collaborations with larger pharmaceutical partners. Key figures in the company's journey include John P. Walker and Corey Goodman, who were instrumental in its early phase, and Nancy Stagliano, Ph.D., who joined as CEO in 2011. Dr. Stagliano, a serial biotech entrepreneur with a background in neuroscience and engineering, steered the company to focus its drug discovery programs on neurodegenerative diseases.

A significant milestone for iPierian was the development of its lead asset, IPN007. This preclinical monoclonal antibody was designed to target a novel form of the secreted Tau protein, which is implicated in a class of neurodegenerative conditions known as Tauopathies, including progressive supranuclear palsy (PSP) and Alzheimer's disease. The company secured substantial funding from a syndicate of prominent investors, including Kleiner Perkins Caufield & Byers, Google Ventures, MPM Capital, and SR One, the venture arm of GlaxoSmithKline. The company's trajectory culminated in its acquisition by Bristol-Myers Squibb in April 2014. The deal was valued at an upfront payment of $175 million, with the potential for an additional $550 million in development and regulatory milestones, showcasing the perceived value of iPierian's Tau-focused pipeline.